Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Past Issues
    • Accepted Articles
    • Email Alerts
    • RSS
    • Terms of Use
  • About PDA JPST
    • JPST Editors and Editorial Board
    • About/Vision/Mission
    • Paper of the Year
  • Author & Reviewer Resources
    • Author Resources / Submit
    • Reviewer Resources
  • JPST Access and Subscriptions
    • PDA Members
    • Institutional Subscriptions
    • Nonmember Access
  • Support
    • Join PDA
    • Contact
    • Feedback
    • Advertising
    • CiteTrack
  • .
    • Visit PDA
    • PDA Letter
    • Technical Reports
    • news uPDATe
    • Bookstore

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
PDA Journal of Pharmaceutical Science and Technology
  • .
    • Visit PDA
    • PDA Letter
    • Technical Reports
    • news uPDATe
    • Bookstore
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
PDA Journal of Pharmaceutical Science and Technology

Advanced Search

  • Home
  • Content
    • Current Issue
    • Past Issues
    • Accepted Articles
    • Email Alerts
    • RSS
    • Terms of Use
  • About PDA JPST
    • JPST Editors and Editorial Board
    • About/Vision/Mission
    • Paper of the Year
  • Author & Reviewer Resources
    • Author Resources / Submit
    • Reviewer Resources
  • JPST Access and Subscriptions
    • PDA Members
    • Institutional Subscriptions
    • Nonmember Access
  • Support
    • Join PDA
    • Contact
    • Feedback
    • Advertising
    • CiteTrack
  • Follow pda on Twitter
  • Visit PDA on LinkedIn
  • Visit pda on Facebook
OtherResearch

Development of Duration-Based Non-Mutagenic Thresholds of Toxicological Concern (TTC) Relevant to Parenteral Extractables and Leachables (E&Ls)

Melisa J. Masuda-Herrera, Joel P. Bercu, Thomas H. Broschard, Anders Burild, Catrin Hasselgren, Patricia Parris, Lucie C. Ford, Jessica Graham, Brad Stanard, Michele Comerford, Daniel Lettiere, Steffen Erler, Courtney M. Callis, Eric Morinello, Wolfgang Muster, Elizabeth A. Martin, Troy R. Griffin, Lee Nagao and Maureen Cruz
PDA Journal of Pharmaceutical Science and Technology January 2022, pdajpst.2021.012693; DOI: https://doi.org/10.5731/pdajpst.2021.012693
Melisa J. Masuda-Herrera
1 Gilead Sciences;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: melisa.masuda-herrera@gilead.com
Joel P. Bercu
1 Gilead Sciences;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: joel.bercu@gilead.com
Thomas H. Broschard
2 Merck KGaA;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: thomas.broschard@merckgroup.com
Anders Burild
3 Novo Nordisk A/S;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: qabu@novonordisk.com
Catrin Hasselgren
4 Genentech, Inc.;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: hasselgren.catrin@gene.com
Patricia Parris
5 Pfizer Worldwide Research and Development;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: patricia.parris@pfizer.com
Lucie C. Ford
6 Texas A&M University;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: lucie.ford@tamu.edu
Jessica Graham
4 Genentech, Inc.;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: graham.jessica@gene.com
Brad Stanard
7 Ultragenyx Pharmaceutical Inc.;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: bstanard@ultragenyx.com
Michele Comerford
8 Pfizer Global Research & Development;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: michele.comerford@pfizer.com
Daniel Lettiere
8 Pfizer Global Research & Development;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Daniel Lettiere
  • For correspondence: daniel.j.lettiere@pfizer.com
Steffen Erler
9 Wella Company;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: steffen.erler@wella.com
Courtney M. Callis
10 Eli Lilly & Company;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: courtney.callis@lilly.com
Eric Morinello
4 Genentech, Inc.;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: morinello.eric@gene.com
Wolfgang Muster
11 Roche Pharmaceutical Research & Early Development;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: wolfgang.muster@roche.com
Elizabeth A. Martin
12 AstraZeneca;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: elizabeth.martin@astrazeneca.com
Troy R. Griffin
13 Teva Branded Pharmaceutical Products R&D;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: troy.griffin@tevapharm.com
Lee Nagao
14 Faegre Drinker Biddle & Reath LLP
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: lee.nagao@faegredrinker.com
Maureen Cruz
14 Faegre Drinker Biddle & Reath LLP
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: maureen.cruz@faegredrinker.com
  • Article
  • Figures & Data
  • Supplemental
  • References
  • Info & Metrics
  • PDF
Loading

Article Information

pdajpst.2021.012693
DOI 
https://doi.org/10.5731/pdajpst.2021.012693
PubMed 
35031541

Published By 
Parenteral Drug Association (PDA)
Print ISSN 
1079-7440
Online ISSN 
1948-2124
History 
  • Received September 24, 2021
  • Accepted January 10, 2022
  • Published online January 14, 2022.

Article Versions

  • You are currently viewing a previous version of this article (January 14, 2022 - 05:26).
  • View the most recent version of this article
Copyright & Usage 
Copyright © 2022, Parenteral Drug Association

Author Information

  1. Melisa J. Masuda-Herrera1,15 (melisa.masuda-herrera{at}gilead.com),
  2. Joel P. Bercu1 (joel.bercu{at}gilead.com),
  3. Thomas H. Broschard2 (thomas.broschard{at}merckgroup.com),
  4. Anders Burild3 (qabu{at}novonordisk.com),
  5. Catrin Hasselgren4 (hasselgren.catrin{at}gene.com),
  6. Patricia Parris5 (patricia.parris{at}pfizer.com),
  7. Lucie C. Ford6 (lucie.ford{at}tamu.edu),
  8. Jessica Graham4 (graham.jessica{at}gene.com),
  9. Brad Stanard7 (bstanard{at}ultragenyx.com),
  10. Michele Comerford8 (michele.comerford{at}pfizer.com),
  11. Daniel Lettiere8 (daniel.j.lettiere{at}pfizer.com),
  12. Steffen Erler9 (steffen.erler{at}wella.com),
  13. Courtney M. Callis10 (courtney.callis{at}lilly.com),
  14. Eric Morinello4 (morinello.eric{at}gene.com),
  15. Wolfgang Muster11 (wolfgang.muster{at}roche.com),
  16. Elizabeth A. Martin12 (elizabeth.martin{at}astrazeneca.com),
  17. Troy R. Griffin13 (troy.griffin{at}tevapharm.com),
  18. Lee Nagao14 (lee.nagao{at}faegredrinker.com) and
  19. Maureen Cruz14 (maureen.cruz{at}faegredrinker.com)
  1. 1 Gilead Sciences;
  2. 2 Merck KGaA;
  3. 3 Novo Nordisk A/S;
  4. 4 Genentech, Inc.;
  5. 5 Pfizer Worldwide Research and Development;
  6. 6 Texas A&M University;
  7. 7 Ultragenyx Pharmaceutical Inc.;
  8. 8 Pfizer Global Research & Development;
  9. 9 Wella Company;
  10. 10 Eli Lilly & Company;
  11. 11 Roche Pharmaceutical Research & Early Development;
  12. 12 AstraZeneca;
  13. 13 Teva Branded Pharmaceutical Products R&D;
  14. 14 Faegre Drinker Biddle & Reath LLP
  1. ↵* Corresponding author; email: melisa.masuda-herrera{at}gilead.com

Cited By...

  • 8 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • Framework for sensitization assessment of extractables and leachables in pharmaceuticals
    Patricia Parris, Geraldine Whelan, Anders Burild, Jessica Whritenour, Uma Bruen, Joel Bercu, Courtney Callis, Jessica Graham, Esther Johann, Troy Griffin, Martin Kohan, Elizabeth A. Martin, Melisa Masuda-Herrera, Brad Stanard, Eric Tien, Maureen Cruz, Lee Nagao
    Critical Reviews in Toxicology 2022 52 2
  • Harmonisation of read-across methodology for drug substance extractables and leachables (E&Ls)
    Melisa Masuda-Herrera, Hannah T. Rosen, Anders Burild, Thomas Broschard, Tyler Bell, Jessica Graham, Troy Griffin, Jedd Hillegass, Penny Leavitt, Brian Huta, Patricia Parris, Uma Bruen, Maureen Cruz, Joel Bercu
    Regulatory Toxicology and Pharmacology 2023 145
  • Evaluating the utility of the Threshold of Toxicological Concern (TTC) and its exclusions in the biocompatibility assessment of extractable chemical substances from medical devices
    Grace Patlewicz, Mark Nelms, Diego Rua
    Computational Toxicology 2022 24
  • Comparison of permitted daily exposure (PDE) values for active pharmaceutical ingredients (APIs) - Evidence of a robust approach
    Claudia Sehner, Tanja Bernier, Kamila Blum, Nicole Clemann, Milica Glogovac, William A. Hawkins, Martin Kohan, Fenneke Linker, Ester Lovsin-Barle, Osahon Osadolor, Thomas Pfister, Elisa Schulze, Markus Schwind, Gregor Tuschl, Lisa Wiesner
    Regulatory Toxicology and Pharmacology 2024 150
  • An in silico workflow for assessing the sensitisation potential of extractables and leachables
    Martyn L. Chilton, Mukesh Patel, Antonio Anax F. de Oliveira
    Computational Toxicology 2023 27
  • Patty's Toxicology
    David G. Dolan, Joel P. Bercu, Jessica C. Graham, Ester L. Barle
    2023
  • Characterization of medical device constituents and development of duration-based non-cancer threshold of toxicological concern values
    Taylor Builee, Todd A. Kennedy, Valériane Levelut, Megan A. Hahn, Stephen Bond, Michael K. Peterson, Frances K. Hsia, Alessia Stornetta, Kristin J. Erickson, Kimberly D. Ehman, Bindu Prabhakar, Bradford D. Bagley, Sherry P. Parker
    Frontiers in Toxicology 2025 7
  • Comprehensive extractables and leachables sensitization analysis and practical application of a risk-based approach to sensitization assessment for parenteral drug products
    Patricia Parris, Geraldine Whelan, Martyn L. Chilton, Claire Beaumont, Anders Burild, Uma Bruen, Courtney Callis, Jessica Graham, Natalia Kovalova, Elizabeth A. Martin, Melisa Masuda-Herrera, Carsten Worsøe, Anissa Alami, Joel Bercu, Dvir Doron, Kristen Dusenbury, Qiang Fu, Troy Griffin, Jedd Hillegass, Esther Johann, Agnes Koenig, Nina Macho, Alina Martirosyan, Kobi Oded, Constança Porredon Guarch, Matthew Schmitz, Brad Stanard, Eric Tien, Erika Udovic, Haiyan Xu, Maureen T. Cruz, Lee Nagao
    Regulatory Toxicology and Pharmacology 2025 157
PreviousNext
Back to top

In This Issue

PDA Journal of Pharmaceutical Science and Technology: 79 (3)
PDA Journal of Pharmaceutical Science and Technology
Vol. 79, Issue 3
May/June 2025
  • Table of Contents
  • Index by Author
  • Complete Issue (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on PDA Journal of Pharmaceutical Science and Technology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Development of Duration-Based Non-Mutagenic Thresholds of Toxicological Concern (TTC) Relevant to Parenteral Extractables and Leachables (E&Ls)
(Your Name) has sent you a message from PDA Journal of Pharmaceutical Science and Technology
(Your Name) thought you would like to see the PDA Journal of Pharmaceutical Science and Technology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
2 + 12 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Development of Duration-Based Non-Mutagenic Thresholds of Toxicological Concern (TTC) Relevant to Parenteral Extractables and Leachables (E&Ls)
Melisa J. Masuda-Herrera, Joel P. Bercu, Thomas H. Broschard, Anders Burild, Catrin Hasselgren, Patricia Parris, Lucie C. Ford, Jessica Graham, Brad Stanard, Michele Comerford, Daniel Lettiere, Steffen Erler, Courtney M. Callis, Eric Morinello, Wolfgang Muster, Elizabeth A. Martin, Troy R. Griffin, Lee Nagao, Maureen Cruz
PDA Journal of Pharmaceutical Science and Technology Jan 2022, pdajpst.2021.012693; DOI: 10.5731/pdajpst.2021.012693

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Development of Duration-Based Non-Mutagenic Thresholds of Toxicological Concern (TTC) Relevant to Parenteral Extractables and Leachables (E&Ls)
Melisa J. Masuda-Herrera, Joel P. Bercu, Thomas H. Broschard, Anders Burild, Catrin Hasselgren, Patricia Parris, Lucie C. Ford, Jessica Graham, Brad Stanard, Michele Comerford, Daniel Lettiere, Steffen Erler, Courtney M. Callis, Eric Morinello, Wolfgang Muster, Elizabeth A. Martin, Troy R. Griffin, Lee Nagao, Maureen Cruz
PDA Journal of Pharmaceutical Science and Technology Jan 2022, pdajpst.2021.012693; DOI: 10.5731/pdajpst.2021.012693
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Data
  • Supplemental
  • References
  • Info & Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • Sensitization Assessment of Extractables and Leachables in Pharmaceuticals: ELSIE Database Analysis
  • Characterizing Extractables and Leachables Chemical Space to Support In Silico Toxicological Hazard Assessments
  • Google Scholar

More in this TOC Section

  • Coring and Fragmentation of Elastomeric Needle Shield in a Pre-Filled Syringe
  • Worldwide Regulatory Reliance: Results of an Executed Chemistry, Manufacturing, and Control Post-Approval Change Pilot
  • Preservative Efficacy Testing of Refrigerated Pharmaceuticals: Choice of Challenging Isolate and Storage Temperature
Show more Research

Similar Articles

Keywords

  • ELSIE
  • Extractables
  • Leachables
  • Parenteral
  • Point of departure
  • Threshold of toxicological concern

Readers

  • About
  • Table of Content Alerts/Other Alerts
  • Subscriptions
  • Terms of Use
  • Contact Editors

Author/Reviewer Information

  • Author Resources
  • Submit Manuscript
  • Reviewers
  • Contact Editors

Parenteral Drug Association, Inc.

  • About
  • Advertising/Sponsorships
  • Events
  • PDA Bookstore
  • Press Releases

© 2025 PDA Journal of Pharmaceutical Science and Technology Print ISSN: 1079-7440  Digital ISSN: 1948-2124

Powered by HighWire